WSU Faculty Pilot Grant Support Program
for Research on the Effects and Outcomes of Cannabis Use
Fall 2017

PURPOSE
The purpose of the Alcohol and Drug Abuse Research Program is to foster research at Washington State University that will provide significant and innovative contributions to behavioral, psychosocial, biomedical or clinical research on alcohol and drug abuse. This announcement by the Alcohol and Drug Abuse Research Program is to request proposals for research on the causes and short- and long-term effects of marijuana use and the outcomes of use. The proposals will be funded by the Dedicated Marijuana Account established by the State of Washington Legislature based on Initiative 502 (at least $100,000 each for FY 2018 and 2019).

Dedicated Marijuana Account funds will be administered by the Alcohol and Drug Abuse Research Program to provide research support for behavioral, psychosocial, biomedical, or clinical investigators to develop their research capabilities; to demonstrate the merit of their research ideas, productivity, and creativity; and to facilitate their ability to obtain extramural research funding or to generate data that is of benefit to the State of Washington and its citizens.

ELIGIBILITY & TERMS OF SUPPORT
Applications will be accepted from WSU investigators who are eligible as principal investigators to apply for funding from extramural agencies such as NIH.

Each award is limited to $25,000. The budget may be composed of two parts and can include equipment that stays at WSU, supplies, pre-paid services, conference travel, consultation fees, and salary support. Awards will be made for a maximum of 20 months. Budget Part A must be expended between November 1, 2017, and June 30, 2018. Budget Part B must be expended between July 1, 2018, and June 30, 2019. Expenditure dates are very strict for this funding source. There will be special expenditure and reporting requirements.

IMPORTANT REGULATIONS
Each faculty member may submit multiple grants as PI. Awards will not count toward the $35,000 cap associated with ADARP awards received through other mechanisms (i.e., Initiative 171 funds) unless there is an overlap between these proposals. PIs are required to address any such overlap in the application.

APPLICATION
This call for grants is designed to promote faculty research on WSU campuses that has potential to advance our understanding of the causes, effects, and outcomes of cannabis use and to provide the foundation for competitive extramural research proposals. Preference will be given to applications that are feasible within the budget period. The PI will be able to demonstrate feasibility at the time of the grant application by submitting documentation indicating (i) receipt of protocol proposal by the WSU Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) and (ii) DEA receipt of application for Schedule 1 Controlled Substances license for cannabis, as needed. Preference will be given to PIs with approved protocols and valid Schedule 1 Controlled Substances licenses.

All applications will be due by 5:00 p.m. on Friday, September 1, 2017. The awards will be effective on November 1, 2017, pending DEA license and approval of human or animal subject protocol by the WSU IRB or IACUC, as needed.

Eligible to Apply:
➢ Tenure track faculty
➢ Research and clinical track faculty with appropriate departmental resources

REVIEW PROCESS
The proposal will be reviewed by a committee of WSU faculty knowledgeable in the area of the proposal. External ad hoc reviewers may be solicited. Most committee members will have had a national competitive award.

Grant proposals should be carefully developed and written to encourage positive consideration of research ideas. Grant applications that do not comply with the page limit and formatting instructions will be returned.
APPLICATION FORMAT

I. E-REX Form
II. Progress Report on previous DMAc grant, if applicable (one page)
III. Face Page (name, position, department, submission date, proposal title, DEA license number – if applicable, IACUC or IRB protocol number, abstract, and proposal type: pilot grant, equipment grant, or shared resources)
IV. Specific Aims (maximum 1 page)
V. Significance
VI. Innovation
VII. Approach
VIII. References
IX. Current NIH-style biosketch
X. Budget Part A - detailed budget with brief justification (to be expended 11/1/17 – 6/30/18)
XI. Budget Part B - detailed budget with brief justification (to be expended 7/1/18 – 6/30/19)
XII. Appendix: IRB, IACUC, DEA documentation of approval or submission (if approval is pending)
XIII. Names of 5-6 possible reviewers, preferably from WSU or UW (optional)

➢ All sections MUST be received electronically by ORSO on time if the grant is to be reviewed.

REVIEW CRITERIA (based on NIH)

1. Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved?
2. Innovation. Does the application challenge and seek to shift current research or clinical practice paradigms by using novel theoretical concepts, approaches or methodologies, instrumentation, or interventions?
3. Approach. Are the overall strategy, methodology, and analyses well reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
4. Investigators. Are the PIs, collaborators, and other researchers well suited to the project? If early stage investigators, do they have appropriate experience and training? If the project is collaborative or multi-PI, do the investigators have complementary and integrated expertise?
5. Extramural Funding Potential/Benefit to the State of Washington. What is the likelihood of the project ultimately receiving extramural support and/or benefiting the State of Washington?
7. Readiness must be considered because these funds are very time-sensitive. Accordingly, any necessary DEA licenses and human and/or animal subject approvals must be in place by the time of review.

ADARP Website: https://adarp.wsu.edu/

INFORMATION

Jenny Baylon, Program Specialist
Alcohol and Drug Abuse Research Program
VBR 233
335-5676
baylonj@vetmed.wsu.edu

OR

Rita Fuchs Lokensgard, Director
Alcohol and Drug Abuse Research Program
VBR 231
335-6164
ritafuchs@vetmed.wsu.edu